{
  "docId": "019dd923-622c-750b-8b9d-167a31878e2a",
  "docSlug": "beab175aaed8",
  "documentTitle": "Bristol-Myers Squibb Company (BMY)",
  "authorId": "03_Starboard_Value",
  "authorName": null,
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2019-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 9,
  "pageCount": 197,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 16,
  "notes": "Uses a visual equation (Historical Acquisitions + Internal R&D = Success) vs (Celgene Acquisition = High Risk/Patent Cliff) to frame the contradiction.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9d-167a31878e2a/9",
  "deckHref": "/decks/019dd923-622c-750b-8b9d-167a31878e2a",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9d-167a31878e2a.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9d-167a31878e2a#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.68,
        "w": 0.28,
        "x": 0.7,
        "y": 0.22
      },
      "kind": "callout",
      "text": "So Why Give it Up for Celgene? Celgene acquisition details, patent cliff, and revenue concentration risks.",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "91750dea-c7e7-41c3-bae0-ce8cb3dedcbe",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.25,
        "x": 0.45,
        "y": 0.25
      },
      "kind": "diagram",
      "text": "Visual equation showing historical acquisitions + internal R&D leading to key products.",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a6bc7210-2210-4604-a196-7751ff65eae5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.85,
        "x": 0.04,
        "y": 0.15
      },
      "kind": "paragraph",
      "text": "The acquisition of Celgene is inconsistent with Bristol-Myers’ historically disciplined approach to M&A.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "94bba424-df83-4a58-9949-e972243adffb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.3,
        "x": 0.01,
        "y": 0.97
      },
      "kind": "source-note",
      "text": "Source: Public company filings, press releases, Starboard estimates.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7253ee89-bc65-4dee-ac59-0ab88db303ce",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.45,
        "x": 0.04,
        "y": 0.25
      },
      "kind": "table",
      "text": "Historical acquisitions table showing PDL, Medarex, Cardioxyl, Flexus, IFM Therapeutics with upfront and contingent payments.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fb45c1c9-0da1-4a76-839a-22123508790a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.92,
        "x": 0.04,
        "y": 0.88
      },
      "kind": "title",
      "text": "The acquisition of Celgene is the antithesis of Bristol-Myers’ “String of Pearls” strategy",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0e5461a2-0b86-4077-93f9-1d56e340d932",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.85,
        "x": 0.04,
        "y": 0.03
      },
      "kind": "title",
      "text": "The Proposed Acquisition Defies Bristol-Myers’ Stated Strategy (cont’d)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "09816015-9033-4c6b-aa47-d560153f6f4a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "antithesis",
      "slug": null,
      "matchId": "9c67a1ef-cb62-48e1-846c-c809a8896994",
      "evidence": "The slide explicitly contrasts the 'String of Pearls' strategy with the Celgene acquisition as an antithesis.",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 24,
      "from": 9,
      "beatId": "1be2f377-bde5-4e96-aa19-6d36bdad8e4b",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate (Make it worse)",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "The presentation agitates the problems, providing more details on the acquisition's flaws and potential risks.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}